<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DALIRESP- roflumilastÂ tabletÂ </strong><br>AstraZeneca Pharmaceuticals LP<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use DALIRESP safely and effectively. See full prescribing information for DALIRESP.<br><br>DALIRESP<span class="Sup">Â®</span> (roflumilast) tablets<br>Initial U.S. Approval: 2011 </div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">DALIRESP is a selective phosphodiesterase 4 inhibitor indicated as a treatment to reduce the risk of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbations</span> in patients with severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> associated with <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> and a history of exacerbations. (<a href="#s1">1</a>, <a href="#s49">14</a>)  </p>
<p class="Highlighta">Limitations of Use<span class="Italics">:</span> DALIRESP is not a bronchodilator and is not indicated for the relief of acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>. (<a href="#s1">1</a>, <a href="#s49">14</a>)  </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">The recommended dosage for patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> is one 500 mcgÂ tablet per day, with or without food. (<a href="#s3">2</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 500 mcg (<a href="#s4">3</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Moderate to severe liver impairment (Child-Pugh B or C) (<a href="#s5">4</a>) </dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>: Do not use for the relief of acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>. (<a href="#s7">5.1</a>) </dd>
<dt>â€¢</dt>
<dd>Psychiatric Events including Suicidality: Advise patients, their caregivers, and families to be alert for the emergence or worsening of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, suicidal thoughts or other <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>, and if such changes occur to contact their healthcare provider. Carefully weigh the risks and benefits of treatment with DALIRESP in patients with a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or suicidal thoughts or behavior. (<a href="#s8">5.2</a>) </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Decrease</span>: Monitor weight regularly. If unexplained or clinically significant <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> occurs, evaluate <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> and consider discontinuation of DALIRESP. (<a href="#s9">5.3</a>) </dd>
<dt>â€¢</dt>
<dd>Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g. rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (<a href="#s10">5.4</a>) </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (â‰¥ 2%) are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>. (<a href="#s12">6.1</a>)  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>. </span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g, erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. The risk of such concurrent use should be weighed carefully against benefit. (<a href="#s15">7.2</a>)  </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Nursing Mothers: DALIRESP should not be used by women who are nursing as excretion of roflumilast and/or its metabolites into human milk is probable and there are no human studies that have investigated effects of DALIRESP on breast-fed infants. (<a href="#s22">8.3</a>)  </p></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
</div>
</div>
</div>
</div>
<div><div></div></div>
<div><div>
<div></div>
<div></div>
</div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 7/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE </a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION </a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS </a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS </a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS </a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Treatment of Acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> </a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Psychiatric Events including Suicidality </a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Decrease</span> </a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Drug Interactions </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS </a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Adverse Reactions in Clinical Trials </a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience </a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS </a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Drugs That Induce Cytochrome P450 (CYP) Enzymes </a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Drugs That Inhibit Cytochrome P450 (CYP) Enzymes </a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Oral Contraceptives Containing Gestodene and Ethinyl Estradiol </a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS </a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy </a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery </a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers </a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use </a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use </a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </a></h2>
<h2><a href="#section-8.7" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE </a></h1>
<h2><a href="#section-9.1" class="toc">10.1 Human Experience </a></h2>
<h2><a href="#section-9.2" class="toc">10.2 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> </a></h2>
<h1><a href="#section-10" class="toc">11 DESCRIPTION </a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY </a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action </a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics </a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics </a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY </a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES </a></h1>
<h2><a href="#section-13.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">Chronic Obstructive Pulmonary Disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>) </a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING </a></h1>
<h2><a href="#section-14.1" class="toc">16.1 How Supplied </a></h2>
<h2><a href="#section-14.2" class="toc">16.2 Storage and Handling </a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION </a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE </h1>
<p class="First">DALIRESP<span class="Sup">Â®</span> is indicated as a treatment to reduce the risk of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbations</span> in patients with severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> associated with <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> and a history of exacerbations. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="s2"></a><a name="section-1.1"></a><p></p>
<p class="First"><span class="Italics">Limitations of Use</span></p>
<p>DALIRESP is not a bronchodilator and is not indicated for the relief of acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s3"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION </h1>
<p class="First">The recommended dose of DALIRESP is one 500 microgram (mcg) tablet per day, with or without food. </p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s4"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS </h1>
<p class="First">DALIRESP is supplied as white to off-white, round tablets, embossed with â€œDâ€? on one side and â€œ500â€? on the other side. Each tablet contains 500 mcg of roflumilast. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s5"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS </h1>
<p class="First">The use of DALIRESP is contraindicated in the following condition: </p>
<p>Moderate to severe liver impairment (Child-Pugh B or C) [<span class="Italics">see Clinical Pharmacology (<a href="#s34">12.3</a>) and Use in Special Populations (<a href="#s25">8.6</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s6"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Treatment of Acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> </h2>
<p class="First">DALIRESP is not a bronchodilator and should not be used for the relief of acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Psychiatric Events including Suicidality </h2>
<p class="First">Treatment with DALIRESP is associated with an increase in psychiatric adverse reactions. In 8 controlled clinical trials 5.9% (263) of patients treated with DALIRESP 500 mcg daily reported psychiatric adverse reactions compared to 3.3% (137) treated with placebo. The most commonly reported psychiatric adverse reactions were <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> which were reported at higher rates in those treated with DALIRESP 500 mcg daily (2.4%, 1.4%, and 1.2% for DALIRESP versus 1.0%, 0.9%, and 0.9% for placebo, respectively) <span class="Italics">[see Adverse Reactions (<a href="#s12">6.1</a>)]</span>. Instances of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and behavior, including <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicide</span>, have been observed in clinical trials. Three patients experienced <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>-related adverse reactions (one <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicide</span> and two <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span>) while receiving DALIRESP compared to one patient (<span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>) who received placebo. Cases of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and behavior, including <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicide</span>, have been observed in the post-marketing setting in patients with or without a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. </p>
<p>Before using DALIRESP in patients with a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or suicidal thoughts or behavior, prescribers should carefully weigh the risks and benefits of treatment with DALIRESP in such patients. Patients, their caregivers, and families should be advised of the need to be alert for the emergence or worsening of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, suicidal thoughts or other <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>, and if such changes occur to contact their healthcare provider. Prescribers should carefully evaluate the risks and benefits of continuing treatment with DALIRESP if such events occur. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Decrease</span> </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight loss</span> was a common adverse reaction in DALIRESP clinical trials and was reported in 7.5% (331) of patients treated with DALIRESP 500 mcg once daily compared to 2.1% (89) treated with placebo [<span class="Italics">see Adverse Reactions (<a href="#s12">6.1</a>)</span>]. In addition to being reported as adverse reactions, weight was prospectively assessed in two placebo-controlled clinical trials of one year duration. In these studies, 20% of patients receiving roflumilast experienced moderate <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> (defined as between 5-10% of body weight) compared to 7% of patients who received placebo.  In addition, 7% of patients who received roflumilast compared to 2% of patients receiving placebo experienced severe (&gt;10% body weight) <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. During follow-up after treatment discontinuation, the majority of patients with <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> regained some of the weight they had lost while receiving DALIRESP. Patients treated with DALIRESP should have their weight monitored regularly. If unexplained or clinically significant <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> occurs, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> should be evaluated, and discontinuation of DALIRESP should be considered. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Drug Interactions </h2>
<p class="First">A major step in roflumilast metabolism is the N-oxidation of roflumilast to roflumilast N-oxide by CYP3A4 and CYP1A2. The administration of the cytochrome P450 enzyme inducer rifampicin resulted in a reduction in exposure, which may result in a decrease in the therapeutic effectiveness of DALIRESP. Therefore, the use of strong cytochrome P450 enzyme inducers (e.g. rifampicin, phenobarbital, carbamazepine, phenytoin) with DALIRESP is not recommended [<span class="Italics">see Drugs That Induce Cytochrome P450 (CYP) Enzymes (<a href="#s14">7.1</a>) and Clinical Pharmacology (<a href="#s34">12.3</a>)</span>]. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s11"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS </h1>
<p class="First">The following adverse reactions are described in greater detail in other sections: </p>
<dl>
<dt>â€¢</dt>
<dd>Psychiatric Events Including Suicidality <span class="Italics">[see Warnings and Precautions (<a href="#s8">5.2</a>)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Decrease</span> <span class="Italics">[see Warnings and Precautions (<a href="#s9">5.3</a>)]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Adverse Reactions in Clinical Trials </h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </p>
<p>The safety data described below reflect exposure of 4438 patients to DALIRESP 500 mcg once daily in four 1-year placebo-controlled trials, two 6-month placebo-controlled trials, and two 6-month drug add-on trials <span class="Italics">[see Clinical Studies (<a href="#s50">14.1</a>)].</span> In these trials, 3136 and 1232 <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> patients were exposed to DALIRESP 500 mcg once daily for 6 months and 1-year, respectively. </p>
<p>The population had a median age of 64 years (range 40-91), 73% were male, 92.9% were Caucasian, and had <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> with a mean pre-bronchodilator forced expiratory volume in one second (FEV<span class="Sub">1</span>) of 8.9 to 89.1% predicted. In these trials, 68.5% of the patients treated with DALIRESP reported an adverse reaction compared with 65.3% treated with placebo. </p>
<p>The proportion of patients who discontinued treatment due to adverse reaction was 14.8% for DALIRESP-treated patients and 9.9% for placebo-treated patients. The most common adverse reactions that led to discontinuation of DALIRESP were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (2.4%) and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (1.6%). </p>
<p>Serious adverse reactions, whether considered drug-related or not by the investigators, which occurred more frequently in DALIRESP-treated patients include <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, lung cancer, prostate cancer, <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>, and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. </p>
<p>Table 1 summarizes the adverse reactions reported by â‰¥ 2% of patients in the DALIRESP group in 8 controlled <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> clinical trials. </p>
<a name="_Reft1"></a><table width="100%">
<caption><span>Table 1: Adverse Reactions Reported by â‰¥ 2% of Patients Treated with DALIRESP 500 mcg daily and Greater Than Placebo </span></caption>
<col width="45%">
<col width="30%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="middle"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Treatment</span></p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="middle"><p class="First"><span class="Bold">Adverse Reactions</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">DALIRESP</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="middle"><p class="First">(Preferred Term) </p></td>
<td class="Botrule Rrule" align="center"><p class="First">(<span class="Bold">N=</span>4438) </p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">(N=</span>4192) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" align="center"><p class="First">n (%) </p></td>
<td class="Botrule Rrule" align="center"><p class="First">n (%) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">420 (9.5) </p></td>
<td class="Botrule Rrule" align="center"><p class="First">113 (2.7) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decreased</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">331 (7.5) </p></td>
<td class="Botrule Rrule" align="center"><p class="First">89 (2.1) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">209 (4.7) </p></td>
<td class="Botrule Rrule" align="center"><p class="First">60 (1.4) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">195 (4.4) </p></td>
<td class="Botrule Rrule" align="center"><p class="First">87 (2.1) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">142 (3.2) </p></td>
<td class="Botrule Rrule" align="center"><p class="First">92 (2.2) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">124 (2.8) </p></td>
<td class="Botrule Rrule" align="center"><p class="First">112 (2.7) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">105 (2.4) </p></td>
<td class="Botrule Rrule" align="center"><p class="First">41 (1.0) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">92 (2.1) </p></td>
<td class="Botrule Rrule" align="center"><p class="First">45 (1.1) </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">91 (2.1) </p></td>
<td class="Botrule Rrule" align="center"><p class="First">15 (0.4) </p></td>
</tr>
</tbody>
</table>
<p>Adverse reactions that occurred in the DALIRESP group at a frequency of 1 to 2% where rates exceeded that in the placebo group include: </p>
<p><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span> - <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span> - <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, </p>
<p>Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span> - <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span> </p>
<p><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span> - <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> </p>
<p>Psychiatric disorders - <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e14"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience </h2>
<p class="First">The following adverse reactions have been identified from spontaneous reports of DALIRESP received worldwide and have not been listed elsewhere. These adverse reactions have been chosen for inclusion due to a combination of seriousness, frequency of reporting or potential causal connection to DALIRESP. Because these adverse reactions were reported voluntarily from a population of uncertain size, it is not possible to estimate their frequency or establish a causal relationship to DALIRESP exposure: Â <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s13"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS </h1>
<p class="First">A major step in roflumilast metabolism is the N-oxidation of roflumilast to roflumilast N-oxide by CYP3A4 and CYP1A2 [<span class="Italics">see Clinical Pharmacology (<a href="#s34">12.3</a>)</span>]. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Drugs That Induce Cytochrome P450 (CYP) Enzymes </h2>
<p class="First">Strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness of DALIRESP. Therefore the use of strong cytochrome P450 inducers (e.g., rifampicin, phenobarbital, carbamazepine, and phenytoin) with DALIRESP is not recommended <span class="Italics">[see Drug Interactions (<a href="#s10">5.4</a>) and Clinical Pharmacology (<a href="#s34">12.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Drugs That Inhibit Cytochrome P450 (CYP) Enzymes </h2>
<p class="First">The co-administration of DALIRESP (500 mcg) with CYP3A4 inhibitors or dual inhibitors that inhibit both CYP3A4 and CYP1A2 simultaneously (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) may increase roflumilast systemic exposure and may result in increased adverse reactions. The risk of such concurrent use should be weighed carefully against benefit <span class="Italics">[see Clinical Pharmacology (<a href="#s34">12.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Oral Contraceptives Containing Gestodene and Ethinyl Estradiol </h2>
<p class="First">The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. The risk of such concurrent use should be weighed carefully against benefit <span class="Italics">[see Clinical Pharmacology (<a href="#s34">12.3</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s17"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS </h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s18"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy </h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s19"></a><a name="section-8.1.1"></a><p></p>
<p class="First">Teratogenic effects: Pregnancy Category C: There are no adequate and well controlled studies of DALIRESP in pregnant women. DALIRESP was not teratogenic in mice, rats, or rabbits. DALIRESP should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
<p>DALIRESP induced <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirth</span> and decreased pup viability in mice at doses corresponding to approximately 16 and 49 times, respectively, the maximum recommended human dose (MRHD) (on a mg/m<span class="Sup">2</span> basis at maternal doses &gt; 2 mg/kg/day and 6 mg/kg/day, respectively). DALIRESP induced post-implantation loss in rats at doses greater than or equal to approximately 10 times the MRHD (on a mg/m<span class="Sup">2</span> basis at maternal doses â‰¥ 0.6 mg/kg/day). No treatment-related effects on embryo-fetal development were observed in mice, rats, and rabbits at approximately 12, 3, and 26 times the MRHD, respectively (on a mg/m<span class="Sup">2</span> basis at maternal doses of 1.5, 0.2, and 0.8 mg/kg/day, respectively). </p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="s20"></a><a name="section-8.1.2"></a><p></p>
<p class="First">Nonteratogenic effects: DALIRESP has been shown to adversely affect pup post-natal development when dams were treated with the drug during pregnancy and lactation periods in mice. These studies found that DALIRESP decreased pup rearing frequencies at approximately 49 times the MRHD (on a mg/mg<span class="Sup">2</span> basis at a maternal dose of 6 mg/kg/day) during pregnancy and lactation. DALIRESP also decreased survival and forelimb grip reflex and delayed pinna detachment in mouse pups at approximately 97 times the MRHD (on a mg/m<span class="Sup">2</span> basis at a maternal dose of 12 mg/kg/day) during pregnancy and lactation. </p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s21"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery </h2>
<p class="First">DALIRESP should not be used during labor and delivery. There are no human studies that have investigated effects of DALIRESP on preterm labor or labor at term; however, animal studies showed that DALIRESP disrupted the labor and delivery process in mice. DALIRESP induced delivery retardation in pregnant mice at doses greater than or equal to approximately 16 times the MRHD (on a mg/m<span class="Sup">2</span> basis at a maternal dose of &gt; 2 mg/kg/day). </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s22"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers </h2>
<p class="First">Roflumilast and/or its metabolites are excreted into the milk of lactating rats. Excretion of roflumilast and/or its metabolites into human milk is probable. There are no human studies that have investigated effects of DALIRESP on breast-fed infants. DALIRESP should not be used by women who are nursing. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s23"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> does not normally occur in children. The safety and effectiveness of DALIRESP in pediatric patients have not been established. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s24"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use </h2>
<p class="First">Of the 4438 <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> subjects exposed to DALIRESP for up to 12 months in 8 controlled clinical trials, 2022 were &gt; 65 years of age and 471 were &gt; 75 years of age. No overall differences in safety or effectiveness were observed between these subjects and younger subjects and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Based on available data for roflumilast, no adjustment of dosage in geriatric patients is warranted <span class="Italics">[see Clinical Pharmacology (<a href="#s34">12.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </h2>
<p class="First">Roflumilast 250 mcg once daily for 14 days was studied in subjects with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> classified as Child-Pugh A and B (8 subjects in each group). The AUCs of roflumilast and roflumilast N-oxide were increased by 51% and 24%, respectively in Child-Pugh A subjects and by 92% and 41%, respectively in Child-Pugh B subjects, as compared to age-, weight- and gender-matched healthy subjects. The C<span class="Sub">max</span> of roflumilast and roflumilast N-oxide were increased by 3% and 26%, respectively in Child-Pugh A subjects and by 26% and 40%, respectively in Child-Pugh B subjects, as compared to healthy subjects. DALIRESP 500 mcg has not been studied in hepatically impaired patients.  Clinicians should consider the risk-benefit of administering DALIRESP to patients who have mild liver impairment (Child-Pugh A). DALIRESP is not recommended for use in patients with moderate or severe liver impairment (Child-Pugh B or C) <span class="Italics">[see Contraindications (<a href="#s5">4</a>) and Clinical Pharmacology (<a href="#s34">12.3</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-8.7"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </h2>
<p class="First">In twelve subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> administered a single dose of 500 mcg roflumilast, the AUCs of roflumilast and roflumilast N-oxide were decreased by 21% and 7%, respectively and C<span class="Sub">max</span> were reduced by 16% and 12%, respectively. No dosage adjustment is necessary for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see Clinical Pharmacology (<a href="#s34">12.3</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s27"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-9.1"></a><p></p>
<h2>10.1 Human Experience </h2>
<p class="First">No case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> has been reported in clinical studies with DALIRESP. During the Phase I studies of DALIRESP, the following symptoms were observed at an increased rate after a single oral dose of 2500 mcg and a single dose of 5000 mcg: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clamminess</span> and arterial <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-9.2"></a><p></p>
<h2>10.2 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> </h2>
<p class="First">In case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, patients should seek immediate medical help. Appropriate supportive medical care should be provided. Since roflumilast is highly protein bound, hemodialysis is not likely to be an efficient method of drug removal.  It is not known whether roflumilast is dialyzable by peritoneal dialysis. </p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s30"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION </h1>
<p class="First">The active ingredient in DALIRESP tablets is roflumilast. Roflumilast and its active metabolite (roflumilast N-oxide) are selective phosphodiesterase 4 (PDE4) inhibitors. The chemical name of roflumilast is N-(3,5-dichloropyridin-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxy-benzamide. Its empirical formula is C<span class="Sub">17</span>H<span class="Sub">14</span>Cl<span class="Sub">2</span>F<span class="Sub">2</span>N<span class="Sub">2</span>O<span class="Sub">3</span> and the molecular weight is 403.22. </p>
<p>The chemical structure is: </p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c9a1d0a8-581f-4f91-a2b8-f419192d0ebf&amp;name=dal00-0006-01.jpg">
</div>
<p>The drug substance is a white to off-white non-hygroscopic powder with a melting point of 160Â°C. It is practically insoluble in water and hexane, sparingly soluble in ethanol and freely soluble in acetone.   </p>
<p>DALIRESP is supplied as white to off-white, round tablets, embossed with â€œDâ€? on one side and â€œ500â€? on the other side. Each tablet contains 500 mcg of roflumilast. </p>
<p>Each tablet of DALIRESP for oral administration contains the following inactive ingredients: lactose monohydrate, corn starch, povidone and magnesium stearate. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s31"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY </h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s32"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action </h2>
<p class="First">Roflumilast and its active metabolite (roflumilast N-oxide) are selective inhibitors of phosphodiesterase 4 (PDE4). Roflumilast and roflumilast N-oxide inhibition of PDE4 (a major cyclic-3â€²,5â€²-adenosine monophosphate (cyclic AMP)-metabolizing enzyme in lung tissue) activity leads to accumulation of intracellular cyclic AMP. While the specific mechanism(s) by which DALIRESP exerts its therapeutic action in <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> patients is not well defined, it is thought to be related to the effects of increased intracellular cyclic AMP in lung cells.  </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s33"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics </h2>
<p class="First">In <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> patients, 4 week treatment with DALIRESP 500 mcg oral once daily reduced <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> and eosinophils by 31%, and 42%, respectively. In a pharmacodynamic study in healthy volunteers, DALIRESP 500 mcg once daily reduced the number of total cells, <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> and eosinophils found in bronchoalveolar lavage fluid following segmental pulmonary lipopolysaccharide (LPS) challenge by 35%, 38% and 73%, respectively. The clinical significance of these findings is unknown. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s34"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Italics">Absorption</span></p>
<p>The absolute bioavailability of roflumilast following a 500 mcg oral dose is approximately 80%. Maximum plasma concentrations (C<span class="Sub">max</span>) of roflumilast typically occur approximately one hour after dosing (ranging from 0.5 to 2 hours) in the fasted state while plateau-like maximum concentrations of the N-oxide metabolite are reached in approximately eight hours (ranging from 4 to 13 hours). Food has no effect on total drug absorption, but delays time to maximum concentration (T<span class="Sub">max</span>) of roflumilast by one hour and reduces C<span class="Sub">max</span> by approximately 40%, however, C<span class="Sub">max</span> and T<span class="Sub">max</span> of roflumilast N-oxide are unaffected. An <span class="Italics">in vitro</span> study showed that roflumilast and roflumilast N-oxide did not inhibit P-gp transporter. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Italics">Distribution</span></p>
<p>Plasma protein binding of roflumilast and its N-oxide metabolite is approximately 99% and 97%, respectively. Volume of distribution for single dose 500 mcg roflumilast is about 2.9Â L/kg. Studies in rats with radiolabeled roflumilast indicate low penetration across the blood-brain barrier. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Italics">Metabolism</span></p>
<p>Roflumilast is extensively metabolized via Phase I (cytochrome P450) and Phase II (conjugation) reactions. The N-oxide metabolite is the only major metabolite observed in the plasma of humans. Together, roflumilast and roflumilast N-oxide account for the majority (87.5%) of total dose administered in plasma. In urine, roflumilast was not detectable while roflumilast N-oxide was only a trace metabolite (less than 1%). Other conjugated metabolites such as roflumilast N-oxide glucuronide and 4-amino-3,5-dichloropyridine N-oxide were detected in urine. </p>
<p>While roflumilast is three times more potent than roflumilast N-oxide at inhibition of the PDE4 enzyme <span class="Italics">in vitro</span>, the plasma AUC of roflumilast N-oxide on average is about 10-fold greater than the plasma AUC of roflumilast. </p>
<p><span class="Italics">In vitro</span> studies and clinical drug-drug interaction studies suggest that the biotransformation of roflumilast to its N-oxide metabolite is mediated by CYP 1A2 and 3A4. Based on further <span class="Italics">in vitro</span> results in human liver microsomes, therapeutic plasma concentrations of roflumilast and roflumilast N-oxide do not inhibit CYP 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4/5, or 4A9/11. Therefore, there is a low probability of relevant interactions with substances metabolized by these P450 enzymes. In addition, <span class="Italics">in vitro</span> studies demonstrated no induction of the CYP 1A2, 2A6, 2C9, 2C19, or 3A4/5 and only a weak induction of CYP 2B6 by roflumilast. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s38"></a><a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Italics">Elimination</span></p>
<p>The plasma clearance after short-term intravenous infusion of roflumilast is on average about 9.6Â L/h. Following an oral dose, the median plasma effective half-life of roflumilast and its N-oxide metabolite are approximately 17 and 30 hours, respectively. Steady state plasma concentrations of roflumilast and its N-oxide metabolite are reached after approximately 4 days for roflumilast and 6 days for roflumilast N-oxide following once daily dosing.  Following intravenous or oral administration of radiolabeled roflumilast, about 70% of the radioactivity was recovered in the urine. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Italics">Special Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-11.3.5.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>Roflumilast 250 mcg once daily for 14 days was studied in subjects with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> classified as Child-Pugh A and B (8 subjects in each group). The AUC of roflumilast and roflumilast N-oxide were increased by 51% and 24%, respectively in Child-Pugh A subjects and by 92% and 41%, respectively in Child-Pugh B subjects, as compared to age-, weight- and gender-matched healthy subjects. The C<span class="Sub">max</span> of roflumilast and roflumilast N-oxide were increased by 3% and 26%, respectively in Child-Pugh A subjects and by 26% and 40%, respectively in Child-Pugh B subjects, as compared to healthy subjects. DALIRESP 500 mcg has not been studied in hepatically impaired patients. Clinicians should consider the risk-benefit of administering DALIRESP to patients who have mild liver impairment (Child-Pugh A).  DALIRESP is not recommended for use in patients with moderate or severe liver impairment (Child-Pugh B or C) <span class="Italics">[see Contraindications (<a href="#s5">4</a>) and Use in Specific Populations (<a href="#s25">8.6</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-11.3.5.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>In twelve subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> administered a single dose of 500 mcg roflumilast, roflumilast and roflumilast N-oxide AUCs were decreased by 21% and 7%, respectively and C<span class="Sub">max</span> were reduced by 16% and 12%, respectively. No dosage adjustment is necessary for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see Use in Specific Populations (<a href="#s26">8.7</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-11.3.5.3"></a><p></p>
<p class="First"><span class="Italics">Age</span></p>
<p>Roflumilast 500 mcg once daily for 15 days was studied in young, middle aged, and elderly healthy subjects. The exposure in elderly (&gt; 65 years of age) were 27% higher in AUC and 16% higher in C<span class="Sub">max</span> for roflumilast and 19% higher in AUC and 13% higher in C<span class="Sub">max</span> for roflumilast-N-oxide than that in young volunteers (18-45 years old). No dosage adjustment is necessary for elderly patients <span class="Italics">[see Use in Specific Populations (<a href="#s24">8.5</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-11.3.5.4"></a><p></p>
<p class="First"><span class="Italics">Gender</span></p>
<p>In a Phase I study evaluating the effect of age and gender on the pharmacokinetics of roflumilast and roflumilast N-oxide, a 39% and 33% increase in roflumilast and roflumilast N-oxide AUC were noted in healthy female subjects as compared to healthy male subjects. No dosage adjustment is necessary based on gender. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-11.3.5.5"></a><p></p>
<p class="First"><span class="Italics">Smoking</span></p>
<p>The pharmacokinetics of roflumilast and roflumilast N-oxide were comparable in smokers as compared to non-smokers. There was no difference in C<span class="Sub">max</span> between smokers and non-smokers when roflumilast 500 mcg was administered as a single dose to 12 smokers and 12 non-smokers. The AUC of roflumilast in smokers was 13% less than that in non-smokers while the AUC of roflumilast N-oxide in smokers was 17% more than that in non-smokers. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-11.3.5.6"></a><p></p>
<p class="First"><span class="Italics">Race</span></p>
<p>As compared to Caucasians, African Americans, Hispanics, and Japanese showed 16%, 41%, and 15% higher AUC, respectively, for roflumilast and 43%, 27%, and 16% higher AUC, respectively, for roflumilast N-oxide. As compared to Caucasians, African Americans, Hispanics, and Japanese showed 8%, 21%, and 5%  higher C<span class="Sub">max</span>, respectively, for roflumilast and 43%, 27%, and 17% higher C<span class="Sub">max</span>, respectively, for roflumilast N-oxide. No dosage adjustment is necessary for race. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-11.3.5.7"></a><p></p>
<p class="First"><span class="Italics">Drug Interactions</span></p>
<p>Drug interaction studies were performed with roflumilast and other drugs likely to be coadministered or drugs commonly used as probes for <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> [<span class="Italics">see Drug Interactions (<a href="#s13">7</a>)].</span> No significant drug interactions were observed when 500 mcg oral roflumilast was administered with inhaled salbutamol, formoterol, budesonide and oral montelukast, digoxin, theophylline, warfarin, sildenafil, midazolam, or antacids. </p>
<p>The effect of concomitant drugs on the exposure of roflumilast and roflumilast N-oxide is shown in the <a href="#_Reffig1">Figure 1</a> below. </p>
<div class="Figure">
<a name="f02"></a><img alt="Figure 1 " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c9a1d0a8-581f-4f91-a2b8-f419192d0ebf&amp;name=dal00-0006-02.jpg">
</div>
<p>Figure 1. Effect of concomitant drugs on the exposure of roflumilast and roflumilast N-oxide. Note that the dashed lines indicate the lower and higher bounds (0.8-1.25) of the 90% confidence interval of the geometric mean ratio of C<span class="Sub">max</span> or AUC for roflumilast or roflumilast N-oxide for Treatment (DALIRESP+Coadministered Drug) vs. Reference (DALIRESP). The dosing regimens of coadministered drugs was: Midazolam:2mg po SD; Erythromycin:500mg po TID; Ketoconazole:200mg po BID; Rifampicin:600mg po QD; Fluvoxamine:50mg po QD; Digoxin:250ug po SD; Maalox:30mL po SD; Salbutamol:0.2mg pi TID; Cimetidine:400mg po BID; Formoterol:40ug po BID; Budesonide:400ug po BID; Theophylline:375mg po BID; Warfarin:250mg po SD; Enoxacin:400mg po BID; Sildenafil:100mg SD; Minulet (combination oral contraceptive):0.075mg gestodene/0.03mg ethinylestradiol po QD; Montelukast:10mg po QD </p>
<p>Drug interactions considered to be significant are described in more detail below <span class="Italics">[also see Drug Interactions (<a href="#s10">5.4</a>) and Drug Interactions (<a href="#s13">7</a>)].</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="e46"></a><a name="section-11.3.5.7.1"></a><p></p>
<p class="First">Inhibitors of CYP3A4 and CYP1A2: </p>
<div class="Section" data-sectionCode="42229-5">
<a name="e47"></a><a name="section-11.3.5.7.1.1"></a><p></p>
<p class="First">Erythromycin: In an open-label crossover study in 16 healthy volunteers, the coadministration of CYP 3A4 inhibitor erythromycin (500 mg three times daily for 13 days) with a single oral dose of 500 mcg DALIRESP resulted in 40% and 70% increase in C<span class="Sub">max</span> and AUC for roflumilast, respectively, and a 34% decrease and a 4% increase in C<span class="Sub">max</span> and AUC for roflumilast N-oxide, respectively. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e48"></a><a name="section-11.3.5.7.1.2"></a><p></p>
<p class="First">Ketoconazole: In an open-label crossover study in 16 healthy volunteers, the coadministration of a strong CYP 3A4 inhibitor ketoconazole (200 mg twice daily for 13 days) with a single oral dose of 500 mcg DALIRESP resulted in 23% and 99% increase in C<span class="Sub">max</span> and AUC for roflumilast, respectively, and a 38% reduction and 3% increase in C<span class="Sub">max</span> and AUC for roflumilast N-oxide, respectively. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e49"></a><a name="section-11.3.5.7.1.3"></a><p></p>
<p class="First">Fluvoxamine: In an open-label crossover study in 16 healthy volunteers, the coadministration of dual CYP 3A4/1A2 inhibitor fluvoxamine (50 mg daily for 14 days) with a single oral dose of 500 mcg DALIRESP showed a 12% and 156% increase in roflumilast C<span class="Sub">max</span> and AUC along with a 210% decrease and 52% increase in roflumilast N-oxide C<span class="Sub">max</span> and AUC, respectively. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e50"></a><a name="section-11.3.5.7.1.4"></a><p></p>
<p class="First">Enoxacin: In an open-label crossover study in 16 healthy volunteers, the coadministration of dual CYP 3A4/1A2 inhibitor enoxacin (400 mg twice daily for 12 days) with a single oral dose of 500 mcg DALIRESP resulted in an increased C<span class="Sub">max</span> and AUC of roflumilast by 20% and 56%, respectively. Roflumilast N-oxide C<span class="Sub">max</span> was decreased by 14% while roflumilast N-oxide AUC was increased by 23%. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e51"></a><a name="section-11.3.5.7.1.5"></a><p></p>
<p class="First">Cimetidine: In an open-label crossover study in 16 healthy volunteers, the coadministration of a dual CYP 3A4/1A2 inhibitor cimetidine (400 mg twice daily for 7 days) with a single dose of 500 mcg oral DALIRESP resulted in a 46% and 85% increase in roflumilast C<span class="Sub">max</span> and AUC; and a 4% decrease in C<span class="Sub">max</span> and 27% increase in AUC for roflumilast N-oxide, respectively. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e52"></a><a name="section-11.3.5.7.2"></a><p></p>
<p class="First">Oral Contraceptives containing Gestodene and Ethinyl Estradiol: </p>
<p>In an open-label crossover study in 20 healthy adult volunteers, coadministration of a single oral dose of 500 mcg DALIRESP with repeated doses of a fixed combination oral contraceptive containing 0.075 mg gestodene and 0.03 mg ethinyl estradiol to steady state caused a 38% increase and 12% decrease in C<span class="Sub">max</span> of roflumilast and roflumilast N-oxide, respectively. Roflumilast and roflumilast N-oxide AUCs were increased by 51% and 14%, respectively. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e53"></a><a name="section-11.3.5.7.3"></a><p></p>
<p class="First">Inducers of CYP enzymes: </p>
<div class="Section" data-sectionCode="42229-5">
<a name="e54"></a><a name="section-11.3.5.7.3.1"></a><p></p>
<p class="First">Rifampicin: In an open-label, three-period, fixed-sequence study in 15 healthy volunteers, coadministration of the strong CYP3A4 inducer rifampicin (600 mg once daily for 11 days) with a single oral dose of 500 mcg DALIRESP resulted in reduction of roflumilast C<span class="Sub">max</span> and AUC by 68% and 79%, respectively; and an increase of roflumilast N-oxide C<span class="Sub">max</span> by 30% and reduced roflumilast N-oxide AUC by 56%. </p>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s47"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY </h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s48"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </h2>
<p class="First">Long-term studies were conducted in hamsters and mice with roflumilast to evaluate its carcinogenic potential. In 2-year oral gavage carcinogenicity studies, roflumilast treatment resulted in dose-related, statistically significant increases in the incidence of undifferentiated carcinomas of nasal epithelium in hamsters at â‰¥ 8 mg/kg/day (approximately 11 times the MRHD based on summed AUCs of roflumilast and its metabolites). The tumorigenicity of roflumilast appears to be attributed to a reactive metabolite of 4-amino-3,5-dichloro-pyridine N-oxide (ADCP N-oxide). No evidence of tumorigenicity was observed in mice at roflumilast oral doses up to 12 and 18 mg/kg/day in females and males, respectively (approximately 10 and 15 times the MRHD, respectively, based on summed AUCs of roflumilast and its metabolites). </p>
<p>Roflumilast tested positive in an <span class="Italics">in vivo</span> mouse micronucleus test, but negative in the following assays: Ames test for bacterial gene mutation, <span class="Italics">in vitro</span> chromosome aberration assay in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, <span class="Italics">in vitro</span> HPRT test with V79 cells, an <span class="Italics">in vitro</span> micronucleus test with V79 cells, DNA adduct formation assay in rat nasal mucosa, liver and testes, and <span class="Italics">in vivo</span> mouse bone marrow chromosome aberration assay. Roflumilast N-oxide was negative in the Ames test and in vitro micronucleus test with V79 cells. </p>
<p>In a human spermatogenesis study, roflumilast 500 mcg had no effects on semen parameters or reproductive hormones during the 3-month treatment period and the following 3-month off-treatment period. In a fertility study, roflumilast decreased fertility rates in male rats at 1.8-mg/kg/day (approximately 29 times the MRHD on a mg/m<span class="Sup">2</span> basis). These rats also showed increases in the incidence of tubular <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, degeneration in the testis and spermiogenic <span class="product-label-link" type="condition" conceptid="4163983" conceptname="Granuloma">granuloma</span> in the epididymides. No effect on male rat fertility rate or reproductive organ morphology was observed at 0.8 mg/kg/day (approximately 13 times the MRHD on a mg/m<span class="Sup">2</span> basis). No effect on female fertility was observed up to the highest roflumilast dose of 1.5 mg/kg/day in rats (approximately 24 times the MRHD on a mg/m<span class="Sup">2</span> basis). </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s49"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-13.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">Chronic Obstructive Pulmonary Disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>) </h2>
<p class="First">The efficacy and safety of DALIRESP (roflumilast) in <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> was evaluated in 8 randomized double-blind, controlled, parallel group clinical trials in 9394 adult patients (4425 receiving DALIRESP 500 mcg) 40 years of age and older with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>. Of the 8 trials, two were placebo-controlled dose selection trials (Trials 1 and 2) of 6 months duration that evaluated the efficacy of DALIRESP 250 mcg and 500 mcg once daily, four were placebo-controlled 1-year trials (Trials 3, 4, 5, and 6) primarily designed to evaluate the efficacy of DALIRESP on <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbations</span>, and two were 6-month efficacy trials (Trials 7 and 8) which assessed the effect of DALIRESP as add-on therapy to a long-acting beta agonist or long-acting anti-muscarinic. The 8 trials enrolled patients with nonreversible obstructive <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> (FEV<span class="Sub">1</span>/FVC â‰¤ 70% and â‰¤ 12% or 200 mL improvement in FEV<span class="Sub">1</span> in response to 4 puffs of albuterol/salbutamol) but the severity of airflow obstruction at baseline was different among the trials. Patients enrolled in the dose selection trials had the full range of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> severity (FEV1 30-80% predicted); median age of 63 years, 73% male, and 99% Caucasian. Patients enrolled in the four exacerbation trials had severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> (FEV<span class="Sub">1</span> â‰¤ 50% predicted); median age of 64 years, 74% male, and 90% Caucasian. Patients enrolled in the two 6-month efficacy trials had moderate to severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> (FEV<span class="Sub">1</span> 40-70% predicted); median age of 65 years, 68% male, and 97% Caucasian. <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbations</span> and lung function (FEV<span class="Sub">1</span>) were co-primary efficacy outcome measures in the four 1-year trials. In the two 6-month supportive efficacy trials, lung function (FEV<span class="Sub">1</span>) alone was the primary efficacy outcome measure. </p>
<p>The two 6-month dose-selection efficacy trials (Trials 1 and 2) explored doses of 250 mcg and 500 mcg once daily in a total of 1929 patients (751 and 724 on DALIRESP 250 and 500 mcg, respectively). The selection of the 500 mcg dose was primarily based on nominal improvements in lung function (FEV<span class="Sub">1</span>) over the 250 mcg dose. The once daily dosing regimen was primarily based on the determination of a plasma half-life of 17 hours for roflumilast and 30 hours for its active metabolite roflumilast N-oxide [<span class="Italics">see Clinical Pharmacology (<a href="#s34">12.3</a>)</span>]. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Italics">Effect on Exacerbations</span></p>
<p>The effect of DALIRESP 500 mcg once daily on <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbations</span> was evaluated in four 1-year trials (Trials 3, 4, 5, and 6). </p>
<p>Two of the trials (Trials 3 and 4) conducted initially enrolled a population of patients with severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> (FEV<span class="Sub">1</span> â‰¤ 50% of predicted) inclusive of those with <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> and/or <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span> who had a history of smoking of at least 10 pack years. Inhaled corticosteroids were allowed as concomitant medications and used in 61% of both DALIRESP and placebo-treated patients and short-acting beta agonists were allowed as rescue therapy. The use of long-acting beta agonists, long-acting anti-muscarinics, and theophylline were prohibited. The rate of moderate or severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbations</span> was a co-primary endpoint in both trials. There was not a symptomatic definition of exacerbation in these 2 trials. Exacerbations were defined in terms of severity requiring treatment with a moderate exacerbation defined as treatment with systemic glucocorticosteroids in Trial 3 or systemic glucocorticosteroids and/or antibiotics in Trial 4 and a severe exacerbation defined as requiring hospitalizations and/or leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in Trial 3 or requiring hospitalization in Trial 4. The trials randomized 1176 patients (567 on DALIRESP) in Trial 3 and 1514 patients (760 on DALIRESP) in Trial 4. Both trials failed to demonstrate a significant reduction in the rate of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbations</span>. </p>
<p>Exploratory analyses of the results of Trials 3 and 4 identified a subpopulation of patients with severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> associated with <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> and <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbations</span> within the previous year that appeared to demonstrate a better response in the reduction of the rate of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbations</span> compared to the overall population. As a result, two subsequent trials (Trial 5 and Trial 6) were conducted that enrolled patients with severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> but associated with <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span>, at least one <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbation</span> in the previous year, and at least a 20 pack-year smoking history. In these trials, long-acting beta agonists and short-acting anti-muscarinics were allowed and were used by 44% and 35% of patients treated with DALIRESP and 45% and 37% of patients treated with placebo, respectively. The use of inhaled corticosteroids was prohibited. As in trials 3 and 4, the rate of moderate exacerbations (defined as requiring intervention with systemic glucocorticosteroids) or severe exacerbations (defined as leading to hospitalization and/or to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) was a co-primary endpoint. </p>
<p>Trial 5 randomized a total of 1525 patients (765 on DALIRESP) and Trial 6 randomized a total of 1571 patients (772 on DALIRESP). In both trials, DALIRESP 500 mcg once daily demonstrated a significant reduction in the rate of moderate or severe exacerbations compared to placebo (<a href="#_Reft2">Table 2</a>). These two trials provide the evidence to support the use of DALIRESP for the reduction of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbations</span>. </p>
<a name="_Reft2"></a><table width="100%">
<caption><span>Table 2. Effect of DALIRESP on Rate of Moderate or  Severe Exacerbations </span></caption>
<col width="9%">
<col width="15%">
<col width="11%">
<col width="24%">
<col width="7%">
<col width="12%">
<col width="23%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="7" valign="top">1. Absolute reduction measured as difference between placebo and roflumilast treated patients.<br>2. RR is Rate Ratio. <br>3. Percent reduction is defined as 100 (1-RR). </td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Study</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Exacerbations Per Patient-Year</span></p></td>
<td class="Botrule Rrule Toprule" colspan="3"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">DALIRESP</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Absolute Reduction<span class="Sup">1</span></span><br></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">RR<span class="Sup">2</span></span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">95% CI</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Percent Reduction</span><span class="Sup">3</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Trial 5 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.1 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.3 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.2 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.85 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.74, 0.98 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">15 </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">Trial 6 </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.2 </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.5 </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.3 </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.82 </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.71, 0.94 </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">18 </p></td>
</tr>
</tbody>
</table>
<p>For patients in Trials 5 and 6 who received concomitant long-acting beta agonists or short-acting anti-muscarinics, reduction of moderate or severe exacerbations with DALIRESP was similar to that observed for the overall populations of the two trials. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Italics">Effect on Lung Function</span></p>
<p>While DALIRESP is not a bronchodilator, all 1-year trials (Trials 3, 4, 5, and 6) evaluated the effect of DALIRESP on lung function as determined by the difference in FEV<span class="Sub">1</span> between DALIRESP and placebo-treated patients (pre-bronchodilator FEV<span class="Sub">1</span> measured prior to study drug administration in three of the trials and post-bronchodilator FEV<span class="Sub">1</span> measured 30 minutes after administration of 4 puffs of albuterol/salbutamol in one trial) as a co-primary endpoint. In each of these trials DALIRESP 500 mcg once daily demonstrated a statistically significant improvement in FEV<span class="Sub">1</span> which averaged approximately 50 mL across the four trials. <a href="#_Reft3">Table 3</a> shows FEV<span class="Sub">1</span> results from Trials 5 and 6 which had demonstrated a significant reduction in <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbations</span>. </p>
<a name="_Reft3"></a><table width="100%">
<caption><span>Table 3. Effect of DALIRESP on FEV<span class="Sub">1</span></span></caption>
<col width="17%">
<col width="27%">
<col width="19%">
<col width="17%">
<col width="20%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="5" valign="top">
<span class="Sup">1</span> Effect measured as difference between DALIRESP and placebo treated patients. </td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First"><span class="Bold">Study</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="4" valign="middle"><p class="First"><span class="Bold">Change in FEV</span><span class="Sub">1 </span><span class="Bold">from Baseline, mL</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="bottom"><p class="First">Trial 5<br></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">DALIRESP</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Effect</span><span class="Sup">1</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">95% CI</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">46 </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">8 </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">39 </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">18, 60 </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">Trial 6<br></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First">33 </p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First">-25 </p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First">58 </p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First">41, 75 </p></td>
</tr>
</tbody>
</table>
<p>Lung function was also evaluated in two 6-month trials (Trials 7 and 8) to assess the effect of DALIRESP when administered as add-on therapy to treatment with a long-acting beta agonist or a long-acting anti-muscarinic. These trials were conducted in a different population of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> patients [moderate to severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> (FEV<span class="Sub">1</span> 40 to 70% of predicted) without a requirement for <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> or frequent history of exacerbations] from that for which efficacy in reduction of exacerbations has been demonstrated and provide safety support to the DALIRESP <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> program.  </p>
<p>No trials have been conducted to assess the effects of DALIRESP on <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbations</span> when added to a fixed-dose combination product containing a long-acting beta agonist and inhaled corticosteroid. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s53"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-14.1"></a><p></p>
<h2>16.1 How Supplied </h2>
<p class="First"> DALIRESP is supplied as white to off-white, round tablets, embossed with â€œDâ€? on one side and â€œ500â€? on the other side. Each tablet contains 500 mcg of roflumilast. </p>
<p> DALIRESP tablets are available: </p>
<dl>
<dt>Â </dt>
<dd>Bottles of 30:Â  Â  Â  Â  Â  Â  Â  Â  Â  Â NDC 0310-0095-30 </dd>
<dt>Â </dt>
<dd>Bottles of 90:Â  Â  Â  Â  Â  Â  Â  Â  Â  Â NDC 0310-0095-90 </dd>
<dt>Â </dt>
<dd>2X10 Unit Dose:Â  Â  Â  Â  Â  Â  Â  NDC 0310-0095-39</dd>
</dl>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="s55"></a><a name="section-14.2"></a><p></p>
<h2>16.2 Storage and Handling </h2>
<p class="First">Store DALIRESP 500 mcg tablets at 20Â° - 25Â°C (68Â° - 77Â°F); excursions permitted to 15Â° - 30Â°C (59Â° - 86Â°F). [See USP Controlled Room Temperature]. </p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s56"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION </h1>
<p class="First"><span class="Italics">See FDA-approved patient labeling (<a href="#_Refs61">Medication Guide</a>). </span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s57"></a><a name="section-15.1"></a><p></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span></span></dd>
</dl>
<p class="First">DALIRESP is not a bronchodilator and should not be used for the relief of acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>. <span class="Italics">[see Warnings and Precautions (<a href="#s7">5.1</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s58"></a><a name="section-15.2"></a><p></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Psychiatric Events including Suicidality</span></dd>
</dl>
<p class="First">Treatment with DALIRESP is associated with an increase in psychiatric adverse reactions. In clinical trials, 5.9% (263) of patients treated with DALIRESP 500 mcg daily reported psychiatric adverse reactions compared to 3.3% (137) treated with placebo. The most commonly reported psychiatric adverse events were <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> which were reported at higher rates in those treated with DALIRESP 500 mcg (2.4%, 1.4%, and 1.2% for DALIRESP versus 1.0%, 0.9%, and 0.9% for placebo, respectively). Instances of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and behavior, including <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicide</span>, have been observed in clinical trials. Three patients experienced <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>-related adverse reactions (one <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicide</span> and two <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span>) while receiving DALIRESP compared to one patient (<span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>) who received placebo. Cases of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and behavior, including <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicide</span>, have been observed in the post-marketing setting in patients with or without a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.   </p>
<p>Before using DALIRESP in patients with a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or suicidal thoughts or behavior, prescribers should carefully weigh the risks and benefits of treatment with DALIRESP in such patients. Patients, their caregivers, and families should be advised of the need to be alert for the emergence or worsening of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, suicidal thoughts or other <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>, and if such changes occur to contact their healthcare provider.  Prescribers should carefully evaluate the risks and benefits of continuing treatment with DALIRESP if such events occur <span class="Italics">[see Warnings and Precautions (<a href="#s8">5.2</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s59"></a><a name="section-15.3"></a><p></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Decrease</span></span></dd>
</dl>
<p class="First"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight loss</span> was a common adverse reaction in DALIRESP clinical trials and was reported in 7.5% (331) of patients treated with DALIRESP 500 mcg once daily compared to 2.1% (89) treated with placebo. In two placebo-controlled clinical trials of one year duration in which weight was prospectively assessed, 20% of patients receiving roflumilast experienced moderate <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> (defined as between 5-10% of body weight) compared to 7% of patients who received placebo and 7% of patients who received roflumilast compared to 2% of patients receiving placebo experienced severe (&gt;10% body weight) <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. During follow-up after treatment discontinuation, the majority of patients with <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> regained some of the weight they had lost while receiving DALIRESP. Patients treated with DALIRESP should have their weight monitored regularly. If unexplained or clinically significant <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> occurs, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> should be evaluated, and discontinuation of DALIRESP should be considered <span class="Italics">[see Warnings and Precautions (<a href="#s9">5.3</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-15.4"></a><p></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Drug Interactions</span></dd>
</dl>
<p class="First">The administration of the cytochrome P450 enzyme inducer rifampicin resulted in a reduction in exposure which may result in a decrease in the therapeutic effectiveness of DALIRESP. Therefore, the use of strong cytochrome P450 enzyme inducers (e.g. rifampicin, phenobarbital, carbamazepine, phenytoin) with DALIRESP is not recommended [<span class="Italics">see Drugs That Induce Cytochrome P450 (CYP) Enzymes (<a href="#s14">7.1</a>) and Clinical Pharmacology (<a href="#s34">12.3</a>)</span>]. </p>
<p>Distributed by:<br>AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850</p>
<p>Under license of Takeda GmbH </p>
<p><span class="Bold">Daliresp<span class="Sup">Â®</span> is a registered trademark of Takeda GmbH.</span></p>
<p>Â© AstraZeneca 2015 </p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="s61"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE</span></p>
<p>DALIRESP<span class="Sup">Â®</span> (da'-li-resp)  </p>
<p>(roflumilast) </p>
<p>Tablets </p>
<p>Read this Medication Guide before you start taking DALIRESP<span class="Sup">Â®</span> and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment. </p>
<p><span class="Bold">What is the most important information I should know about DALIRESP?</span></p>
<p><span class="Bold">DALIRESP can cause serious side effects.</span> Tell your healthcare provider right away if you have any of the symptoms listed below while taking DALIRESP. </p>
<dl>
<dt>1.</dt>
<dd>
<span class="Bold"> DALIRESP may cause mental health problems including suicidal thoughts and behavior.</span> Some people taking DALIRESP may develop mood or behavior problems including:<dl>
<dt>â€¢</dt>
<dd>thoughts of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying </dd>
<dt>â€¢</dt>
<dd>attempt to commit <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> </dd>
<dt>â€¢</dt>
<dd>trouble sleeping (<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>) </dd>
<dt>â€¢</dt>
<dd>new or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> </dd>
<dt>â€¢</dt>
<dd>new or worse <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> </dd>
<dt>â€¢</dt>
<dd>acting on dangerous impulses </dd>
<dt>â€¢</dt>
<dd>other unusual changes in your behavior or mood </dd>
</dl>
</dd>
<dt>2.</dt>
<dd>
<span class="Bold"> <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight loss</span>.</span> DALIRESP can cause <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. You should check your weight on a regular basis. You will also need to see your healthcare provider regularly to have your weight checked.  If you notice that you are losing weight, call your healthcare provider. Your healthcare provider may ask you to stop taking DALIRESP if you lose too much weight. </dd>
</dl>
<p><span class="Bold">DALIRESP may affect the way other medicines work, and other medicines may affect how DALIRESP works.</span> Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. </p>
<p><span class="Bold">What is DALIRESP?</span></p>
<p>DALIRESP is a prescription medicine used in adults with severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">Chronic Obstructive Pulmonary Disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>) to decrease the number of flare-ups or the worsening of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> symptoms (exacerbations). </p>
<p><span class="Bold">DALIRESP is not a bronchodilator and should not be used for treating sudden breathing problems.</span> Your healthcare provider may give you other medicine to use for sudden breathing problems. </p>
<p>It is not known if DALIRESP is safe and effective in children. </p>
<p><span class="Bold">Who should not take DALIRESP?</span></p>
<p><span class="Bold">Do not take DALIRESP if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>have certain liver problems. Talk with your healthcare provider before you take DALIRESP if you have liver problems. </dd>
</dl>
<p><span class="Bold">What should I tell my healthcare provider before taking DALIRESP?</span></p>
<p>Before you take DALIRESP, tell your healthcare provider if you: </p>
<dl>
<dt>â€¢</dt>
<dd>have or have had a history of mental health problems including <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span>. </dd>
<dt>â€¢</dt>
<dd>have liver problems </dd>
<dt>â€¢</dt>
<dd>have any other medical conditions </dd>
<dt>â€¢</dt>
<dd>are pregnant or plan to become pregnant.  It is not known if DALIRESP will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant. </dd>
<dt>â€¢</dt>
<dd>are breastfeeding or plan to breastfeed.  It is not known if DALIRESP passes into your breast milk. You and your healthcare provider should decide if you will take DALIRESP or breastfeed.  You should not do both. </dd>
</dl>
<p><span class="Bold">How should I take DALIRESP?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Take DALIRESP exactly as your healthcare provider tells you to take it. </dd>
<dt>â€¢</dt>
<dd>DALIRESP can be taken with or without food. </dd>
<dt>â€¢</dt>
<dd>If you take more than your prescribed dose of DALIRESP, call your healthcare provider or go to the nearest hospital emergency room right away. </dd>
</dl>
<p><span class="Bold">What are the possible side effects of DALIRESP?</span></p>
<p><span class="Bold">DALIRESP can cause serious side effects, including:</span></p>
<p>See â€œ<span class="Bold"><a href="#_Refp01">What is the most important information I should know about DALIRESP?</a></span>â€? </p>
<p><span class="Bold">The most common side effects of DALIRESP include:</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4153160" conceptname="Influenza-like symptoms">flu like symptoms</span> </dd>
<dt>â€¢</dt>
<dd>problems sleeping (<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>) </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span> </dd>
</dl>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. </p>
<p>These are not all the possible side effects of DALIRESP. </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
<p><span class="Bold">How do I store DALIRESP Tablets?</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Store DALIRESP at 68Â°F to 77Â°F (20Â°C to 25Â°C); excursions permitted to 15Â° - 30Â°C (59Â° - 86Â°F). [See USP Controlled Room Temperature].</span></dd>
</dl>
<p><span class="Bold">Keep DALIRESP Tablets and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about DALIRESP</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use DALIRESP for a condition for which it was not prescribed. Do not give DALIRESP to other people, even if they have the same symptoms that you have. It may harm them. </p>
<p>This Medication Guide summarizes the most important information about DALIRESP. For more information about DALIRESP, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about DALIRESP that is written for health professionals. </p>
<p>For more information about DALIRESP call 1-800-236-9933. </p>
<p><span class="Bold">What are the ingredients in DALIRESP?</span></p>
<p><span class="Bold">Active ingredient:</span> roflumilast<br><span class="Bold">Inactive ingredients:</span> lactose monohydrate, corn starch, povidone and magnesium stearate. </p>
<p><span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
<p>Rev. 07/2015 </p>
<p> Distributed by: <br>AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850</p>
<p>Under license of Takeda GmbH</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s62"></a><a name="section-17"></a><p></p>
<p class="First">Principal Display Panel â€“ 30 Tablets Bottle Label </p>
<p>Rx Only                               NDC 0310-0095-30 </p>
<p><span class="Italics">Daliresp</span><span class="Sup">Â®</span></p>
<p>(roflumilast) tablets </p>
<p>500 mcg per tablet </p>
<p>Dispense the accompanying Medication Guide to each patient </p>
<p>30 Tablets </p>
<p><span class="Bold">AstraZeneca</span></p>
<div class="Figure">
<a name="f03"></a><img alt="Principal Display Panel 30 Tablets Bottle Label " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c9a1d0a8-581f-4f91-a2b8-f419192d0ebf&amp;name=dal00-0006-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s63"></a><a name="section-18"></a><p></p>
<p class="First">Principal Display Panel â€“ Carton Label</p>
<p>Rx Only NDC 0310-0095-39</p>
<p>Daliresp<span class="Sup">Â®</span></p>
<p>(roflumilast) tablets</p>
<p>500 mcg</p>
<p>Each tablet contains 500 mcg of roflumilast.</p>
<p><span class="Bold">Dispense the accompanying Medication Guide to each patient.</span></p>
<p>20 Tablets (2 x 10 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards).</p>
<div class="Figure">
<a name="f04"></a><img alt="Principal Display Panel â€“ Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c9a1d0a8-581f-4f91-a2b8-f419192d0ebf&amp;name=dal00-0006-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DALIRESPÂ 		
					</strong><br><span class="contentTableReg">roflumilast tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0310-0095</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>roflumilast</strong> (roflumilast) </td>
<td class="formItem">roflumilast</td>
<td class="formItem">500Â ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">5mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">D;500</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0310-0095-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem">07/01/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0310-0095-90</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem">07/01/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0310-0095-39</td>
<td class="formItem">10  in 1 BOX, UNIT-DOSE</td>
<td class="formItem">07/01/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">2  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:0310-0095-95</td>
<td class="formItem">7  in 1 BOX, UNIT-DOSE</td>
<td class="formItem">07/01/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022522</td>
<td class="formItem">07/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>AstraZeneca Pharmaceuticals LP
							(054743190)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>AstraZeneca (230790719)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c9a1d0a8-581f-4f91-a2b8-f419192d0ebf</div>
<div>Set id: c9a1d0a8-581f-4f91-a2b8-f419192d0ebf</div>
<div>Version: 1</div>
<div>Effective Time: 20150701</div>
</div>
</div>Â <div class="DistributorName">AstraZeneca Pharmaceuticals LP</div></p>
</body></html>
